Stereotactic radiosurgery for pediatric brain arteriovenous malformations: long-term outcomes

Ching-Jen Chen, MD,¹ Cheng-Chia Lee, MD, PhD,²,³ Hideyuki Kano, MD, PhD,⁴ Kathryn N. Kearns, BS,¹ Dale Ding, MD,⁵ Shih-Wei Tzeng, MD,² Ahmet Atik, MD,⁶ Krishna Joshi, MD,⁶ Gene H. Barnett, MD,⁶ Paul P. Huang, MD,⁷ Douglas Kondziolka, MD,⁷ David Mathieu, MD,⁴ Christian Iorio-Morin, MD, PhD,⁴ Inga S. Grills, MD,⁹ Thomas J. Quinn, MD,⁹ Zaid A. Siddiqui, MD,⁹ Kim Marvin, BS,⁹ Caleb Feliciano, MD,⁸ Andrew Faramand, MD,⁴ L. Dade Lunsford, MD,⁴ and Jason P. Sheehan, MD, PhD,¹ on behalf of the International Radiosurgery Research Foundation

OBJECTIVE Contrary to the better described obliteration- and hemorrhage-related data after stereotactic radiosurgery (SRS) of brain arteriovenous malformations (AVMs) in pediatric patients, estimates of the rarer complications, including cyst and tumor formation, are limited in the literature. The aim of the present study was to assess the long-term outcomes and risks of SRS for AVMs in pediatric patients (age < 18 years).

METHODS The authors retrospectively analyzed the International Radiosurgery Research Foundation pediatric AVM database for the years 1987 to 2018. AVM obliteration, post-SRS hemorrhage, cyst formation, and tumor formation were assessed. Cumulative probabilities, adjusted for the competing risk of death, were calculated.

RESULTS The study cohort comprised 539 pediatric AVM patients (mean follow-up 85.8 months). AVM obliteration was observed in 64.3% of patients, with cumulative probabilities of 63.6% (95% CI 58.8%–68.0%), 77.1% (95% CI 72.1%–81.3%), and 88.1% (95% CI 82.5%–92.0%) over 5, 10, and 15 years, respectively. Post-SRS hemorrhage was observed in 8.4% of patients, with cumulative probabilities of 4.9% (95% CI 3.1%–7.2%), 9.7% (95% CI 6.4%–13.7%), and 14.5% (95% CI 9.5%–20.5%) over 5, 10, and 15 years, respectively. Cyst formation was observed in 2.1% of patients, with cumulative probabilities of 5.5% (95% CI 2.3%–10.7%) and 6.9% (95% CI 3.1%–12.9%) over 10 and 15 years, respectively. Meningiomas were observed in 2 patients (0.4%) at 10 and 12 years after SRS, with a cumulative probability of 3.1% (95% CI 0.6%–9.7%) over 15 years.

CONCLUSIONS AVM obliteration can be expected after SRS in the majority of the pediatric population, with a relatively low risk of hemorrhage during the latency period. Cyst and benign tumor formation after SRS can be observed in 7% and 3% of patients over 15 years, respectively. Longitudinal surveillance for delayed neoplasia is prudent despite its low incidence.


KEYWORDS arteriovenous malformation; complication; cyst; neoplasm; pediatric; radiation; radiosurgery; stroke; vascular disorders
BRAIN arteriovenous malformations (AVMs) are responsible for approximately 50% of all spontaneous intracranial hemorrhages occurring in the pediatric population (age < 18 years). The substantial cumulative risk of AVM hemorrhage over a child’s lifetime generally outweighs the risk of intervention, which generally favors an aggressive approach toward AVM management in the pediatric population. Stereotactic radiosurgery (SRS) is an effective intervention, either primarily or as a component of multimodality treatment, for pediatric AVMs, especially those not amenable to surgery or in patients who are unwilling or unable to undergo surgery. The limitations of existing pediatric AVM studies include single-center data, small sample size, heterogeneous patient populations that include adult patients, lack of time-dependent analysis, and failure to account for the competing risk of death. In order to better inform the long-term outcomes and risks of SRS for pediatric AVMs, we performed a multicenter, retrospective cohort analysis of individual patient data pooled from 8 member institutions of the International Radiosurgery Research Foundation (IRRF).

**Methods**

**Patient Identification, Ethical Approval of Study, and Informed Consent**

This study follows the guidelines set forth by the STROBE checklist. This study was approved by the IRB at each individual institution, and patient consent was waived by each IRB. We retrospectively reviewed a database of pediatric AVM patients (age < 18 years at the time of initial SRS) who underwent SRS at 8 institutions participating in the IRRF. Data on pediatric AVM patients from the previous comprehensive IRRF database (1987–2014) were updated retrospectively by each respective institution to include additional patients and follow-up data on outcomes and complications occurring up to and including 2018. Any pediatric AVM patients who were excluded in the previous database due to treatment with repeat SRS or inadequate follow-up were included in this updated database. The current database also included pediatric AVM patients who underwent SRS between 2014 and 2018, and data from additional participating institutions were included. Verification and attestation of data accuracy were performed by each respective institution. Individual patient data from each contributing institution were then de-identified and pooled by an independent third party.

**Baseline Data and Variables**

Baseline patient data included patient characteristics, AVM features, and SRS treatment parameters. Eloquent locations included the sensorimotor, language, and visual cortex, hypothalamus and thalamus, internal capsule, brainstem, cerebellar peduncles, and deep cerebellar nuclei. Deep locations included the thalamus, basal ganglia, and brainstem. The Spetzler-Martin (SM) grade, modified radiosurgery-based AVM score, and Virginia Radiosurgery AVM Scale score were calculated for each AVM. SRS was performed using the Gamma Knife, and the specific model used varied by year and availability at each institution. The SRS technique for AVMs has been previously described. In brief, the patient’s calvaria was affixed within a Leksell model G frame (Elekta AB) under anesthesia. The nidal angioarchitecture and spatial anatomy of the AVM were delineated on DSA and thin-slice (slice thickness 1–2 mm) contrast-enhanced MRI or on CTA when MRI was contraindicated.

**Follow-Up and Outcomes**

Neuroimaging follow-up, comprising MRI or CTA when MRI was contraindicated, was performed at 6-month intervals for the first 2 years after SRS and then annually thereafter. Patients with complete AVM obliteration on follow-up MRI were recommended to undergo confirmatory DSA. AVM obliteration was defined on MRI as a lack of abnormal flow voids or on DSA as an absence of anomalous arteriovenous shunting.

Radiation-induced changes (RICs) were radiologically defined as perinidal hyperintensities on T2-weighted or FLAIR MRI sequences. Symptomatic RICs were defined as RICs associated with any new or worsening neurological deterioration. Permanently symptomatic RICs were defined as symptomatic RICs without neurological recovery. Post-SRS hemorrhage was defined as any AVM-related intracranial hemorrhage during the latency period (time period between initial SRS treatment and AVM obliteration), regardless of associated neurological symptoms or lack thereof. Hemorrhages that occurred after AVM obliteration were also captured. SRS-associated cyst and tumor formation were also recorded. The composite endpoint of favorable outcome was defined as AVM obliteration without post-SRS hemorrhage or permanently symptomatic RICs. The follow-up period comprised clinical and neuroimaging follow-up, whichever was longer.

**Statistical Analysis**

All statistical analyses were performed using Stata (version 14.2, StataCorp). The follow-up duration was defined as the time interval from SRS to death or last follow-up. Rates of defined outcomes and complications, comprising favorable outcome, AVM obliteration, post-SRS hemorrhage, RICs (radiological, symptomatic, and permanent), cyst formation, and tumor formation, were reported as percentages. Incidences of post-SRS hemorrhage, cyst formation, and tumor formation were reported as number of new cases divided by the amount of patient-time at risk with 95% confidence intervals. To account for the competing risk of death and to avoid biased estimates of incidence, cumulative incidence and associated 95% CIs of AVM obliteration, post-SRS hemorrhage, cyst formation, and tumor formation were calculated using nonparametric cumulative incidence functions. Subgroup analyses were performed for pediatric AVM patients who underwent single-session SRS (i.e., no repeat SRS) and those who underwent single-session SRS as the only AVM treatment (i.e., no resection, embolization, or repeat SRS). Missing data were not imputed.

**Results**

**Study Cohort Composition**

The study cohort comprised 539 pediatric patients with
brain AVMs. The contribution from each participating center included 193 patients from the University of Virginia, 173 patients from Taipei Veterans General Hospital, 135 patients from the University of Pittsburgh, 12 patients from the Cleveland Clinic, 9 patients from the Beaumont Health System, 8 patients from the University of Puerto Rico, 7 patients from New York University, and 2 patients from the University of Sherbrooke.

Table 1 details the patient, AVM, and SRS characteristics of the study cohort. The mean age of patients was 12.8 years, and 47.3% were female. Prior AVM hemorrhage occurred in 71.6%. Prior AVM interventions included external-beam radiation therapy (EBRT), resection, and embolization in 12.8%, 6.1%, and 16.9%, respectively. The mean AVM maximum diameter and nidus volume were 2.6 cm and 5.9 cm$^3$, respectively. AVMs were localized to eloquent and deep brain areas in 75.9% and 34%, respectively. AVM-associated arterial aneurysms and deep venous drainage were present in 6.3% and 64%, respectively. The mean SRS margin dose was 20.2 Gy, and the median number of isocenters was 4. Repeat SRS was performed in 21.4% of the patients. The repeat SRS were performed for incomplete AVM obliteration after the initial SRS procedure. The number of patients who underwent 2, 3, 4, and 5 SRS procedures was 104, 7, 1, and 1, respectively. The mean follow-up duration after initial SRS was 85.8 months.

Outcomes and Complications of the Overall Cohort

Table 2 details the outcomes and complications of the study cohort. A favorable outcome was achieved in 57% of the patients, and AVM obliteration was achieved in 64.3% of the patients. Of those in whom obliteration was achieved, 12.7% did not have confirmation by DSA. Of the entire cohort, 3.9% of the patients had obliteration demonstrated on MRI, but on DSA a residual nidus was present. The cumulative incidence of AVM obliteration after SRS was 63.6% (95% CI 58.8%–68.0%), 77.1% (95% CI 72.1%–81.3%), and 88.1% (95% CI 82.5%–92.0%) over 5, 10, and 15 years, respectively (Fig. 1A). Of the patients who underwent multiple SRS procedures, obliteration was achieved in 47.8% at the last follow-up. The incidence of post-SRS hemorrhage was 10.7 (95% CI 7.8–14.7) per 1000 patient-years. Hemorrhage after AVM obliteration occurred in 6 patients (1.7%; 5 confirmed by DSA, 1 determined by MRI only) at a median interval of 41.6 months (range 38.1–55.9 months) after obliteration. The cumulative incidence of post-SRS hemorrhage was 4.9% (95% CI 3.1%–7.2%), 9.7% (95% CI 6.4%–13.7%), and 14.5% (95% CI 9.5%–20.5%) over 5, 10, and 15 years, respectively (Fig. 1B).

The rates of radiological, symptomatic, and permanently symptomatic RICs were 38.4%, 10.3%, and 6.2%, respectively. Delayed cyst formation occurred in 2.1% at a median interval of 7.6 years after SRS. The incidence of cyst formation was 4.4 (95% CI 2.5–8.0) per 1000 patient-years. The cumulative incidence of cyst formation was 1.4% (95% CI 0.5%–3.1%), 5.5% (95% CI 2.3%–10.7%), and 6.9% (95% CI 3.1%–12.9%) over 5, 10, and 15 years, respectively (Fig. 1C). Tumor formation was observed in 2 patients (0.4%), and both lesions were benign meningiomas detected at 10 and 12 years after SRS. These were managed conservatively. The incidence of tumor formation was 0.8 (95% CI 0.2–3.2) per 1000 patient-years. The cumulative incidence of tumor formation was 3.1% (95% CI 0.6%–9.7%) over 15 years (Fig. 1D).

Subgroup Analysis of SM Grade I and II AVMs

Table 3 details the outcomes and complications of SM grade I and II AVMs. A favorable outcome was achieved in 64%. The cumulative incidence of AVM obliteration after SRS was 75.5% (95% CI 67.9%–81.5%), 85.3% (95% CI 77.9%–90.4%), and 95.5% (95% CI 80.2%–99.0%) over 5, 10, and 15 years, respectively. The cumulative incidence of post-SRS hemorrhage was 3.6% (95% CI 1.3%–7.9%), 5.5% (95% CI 2.0%–11.8%), and 12.0% (95% CI 4.2%–24.3%) over 5, 10, and 15 years, respectively. The cumulative incidence of cyst formation was 1.5% (95% CI 0.3%–5.0%), 5.3% (95% CI 0.8%–16.4%), and 5.3% (95% CI 0.8%–16.4%) over 5, 10, and 15 years, respectively. The cumulative incidence of tumor formation was 4.7% (95% CI 0.3%–19.6%) over 15 years.

Outcomes and Complications of Single-Session SRS

Single-session SRS was performed as the only AVM treatment for 416 pediatric AVMs (Table 1). The mean age of the patients in this subgroup was 12.9 years, and 47.3% were female. Prior AVM hemorrhage occurred in 71.6% of the patients. Prior AVM interventions included EBRT, resection, and embolization in 7.5%, 5.8%, and 16.6%, respectively. The mean AVM maximum diameter and nidus volume were 2.4 cm and 5.2 cm$^3$, respectively. AVMs were localized to eloquent and deep brain areas in 74% and 32%, respectively. AVM-associated arterial aneurysms and deep venous drainage were present in 6.7% and 61.5%, respectively. The mean SRS margin dose was 20.3 Gy, and the median number of isocenters was 4. The mean follow-up duration was 76.9 months. A favorable outcome was achieved in 63% (Table 2). The cumulative incidence of AVM obliteration after SRS was 76.5% (95% CI 71.4%–80.8%), 83.8% (95% CI 78.6%–87.8%), and 91.7% (95% CI 85.9%–95.2%) over 5, 10, and 15 years, respectively (Fig. 2A). The incidence of post-SRS hemorrhage was 7.2 (95% CI 4.5–11.4) per 1000 patient-years. The cumulative incidence of post-SRS hemorrhage was 4.2% (95% CI 2.3%–6.8%), 5.3% (95% CI 2.8%–8.9%), and 7.1% (95% CI 3.4%–12.7%) over 5, 10, and 15 years, respectively (Fig. 2B).

The rates of radiological, symptomatic, and permanently symptomatic RICs were 36.5%, 8.5%, and 5.3%, respectively. Delayed cyst formation occurred in 1.2% at a median interval of 3 years after SRS. The incidence of cyst formation was 3.1 (95% CI 1.3–7.4) per 1000 patient-years. The cumulative incidence of cyst formation was 1.3% (95% CI 0.3%–3.7%), 2.7% (95% CI 0.7%–7.2%), and 2.7% (95% CI 0.7%–7.2%) over 5, 10, and 15 years, respectively (Fig. 2C). The incidence of tumor formation was 0.6 (95% CI 0.09–4.4) per 1000 patient-years. The cumulative incidence of tumor formation was 2.3% (95% CI 0.2%–10.5%) over 15 years (Fig. 2D).

Outcomes and Complications of Single-Session SRS as the Only AVM Treatment

Single-session SRS was performed as the only AVM...
The mean age of this subgroup was 13 years, and 46.6% were female. Prior A VM hemorrhage occurred in 72.1% of the patients. The mean A VM maximum diameter and nidus volume were 2.4 cm and 5.1 cm$^3$, respectively. A VMs were localized to eloquent and deep brain areas in 75.4% and 34.1%, respectively. A VM-associated arterial aneurysms and deep venous drainage were present in 6.2% and 63%, respectively. The mean SRS margin dose was 20.1 Gy, and the median number of isocenters was 5. The mean follow-up duration was 75.8 months. A favorable outcome was achieved in 66% (Table 2). The cumulative incidence of A VM obliteration after SRS was 79.1% (95% CI 73.3%–83.7%), 87.7% (95% CI 81.8%–91.8%), and 93.5% (95% CI 87.3%–96.8%) over 5, 10, and 15 years, respectively (Fig. 3A). The incidence of post-SRS hemorrhage was 7.1 (95% CI 4.1–12.2) per 1000 patient-years. The cumulative incidence of post-SRS hemorrhage was 4.0% (95% CI 2.0%–7.1%), 4.0% (95% CI 2.0%–7.1%), and 6.6% (95% CI 2.5%–13.5%) over 5, 10, and 15 years, respectively (Fig. 3B).

The rates of radiological, symptomatic, and permanently symptomatic RICs were observed in 40.4%, 7.3%, and 4.6% of the patients, respectively. Delayed cyst formation occurred in 1.3% at a median interval of 2.5 years after SRS. The incidence of cyst formation was 3.5 (95% CI 1.3–9.3) per 1000 patient-years. The cumulative incidence of cyst formation was 1.9% (95% CI 0.5%–5.1%), 4.0% (95% CI 1.0%–10.7%), and 4.0% (95% CI 1.0%–10.7%) over 5, 10, and 15 years, respectively (Fig. 3C). No tumor formation was observed in this subgroup.

### TABLE 1. Patient, AVM, and SRS characteristics of the study cohort

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Overall Cohort (n = 539)</th>
<th>Single-Session SRS (n = 416)</th>
<th>Single-Session SRS as Only Treatment (n = 305)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age: mean; median (SD), yrs</td>
<td>12.8; 13.3 (3.7)</td>
<td>12.9; 13.4 (3.6)</td>
<td>13; 13.7 (3.7)</td>
</tr>
<tr>
<td>Female, no. (%)</td>
<td>255/539 (47.3)</td>
<td>199/416 (48.7)</td>
<td>142/305 (46.6)</td>
</tr>
<tr>
<td>Prior AVM hemorrhage, no. (%)</td>
<td>386/539 (71.6)</td>
<td>298/416 (71.6)</td>
<td>220/305 (72.1)</td>
</tr>
<tr>
<td>Prior EBRT, no. (%)</td>
<td>69/539 (12.8)</td>
<td>31/416 (7.5)</td>
<td>—</td>
</tr>
<tr>
<td>Prior resection, no. (%)</td>
<td>33/59 (6.1)</td>
<td>24/416 (5.8)</td>
<td>—</td>
</tr>
<tr>
<td>Prior embolization, no. (%)</td>
<td>91/539 (16.8)</td>
<td>69/416 (16.8)</td>
<td>—</td>
</tr>
<tr>
<td>Max diameter: mean; median (SD), cm</td>
<td>2.6; 2.3 (1.4)</td>
<td>2.4; 2.2 (1.2)</td>
<td>2.4; 2.2 (1.2)</td>
</tr>
<tr>
<td>Volume: mean; median (SD), cm$^3$</td>
<td>5.9; 10.2</td>
<td>5.2; 9.1</td>
<td>5.1; 2.9 (6.9)</td>
</tr>
<tr>
<td>≥2 SRS treatments, no. (%)</td>
<td>113/529 (21.4)</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>Max dose: mean; median (SD), Gy*</td>
<td>36.7; 36 (7.3)</td>
<td>36.8; 36 (7.1)</td>
<td>36.4; 34 (7.3)</td>
</tr>
<tr>
<td>Margin dose: mean; median (SD), Gy*</td>
<td>20.2; 30 (3.3)</td>
<td>20.3; 30 (3.1)</td>
<td>20.1; 19.5 (3.1)</td>
</tr>
<tr>
<td>Isodose, median (IQR), %</td>
<td>50 (50–58)</td>
<td>50 (50–59)</td>
<td>51.4 (50–58)</td>
</tr>
<tr>
<td>Isocenters, median (IQR), %</td>
<td>4 (2–9)</td>
<td>4 (2–9)</td>
<td>5 (2–10)</td>
</tr>
<tr>
<td>Eloquent location, no. (%)†</td>
<td>409/539 (75.9)</td>
<td>308/416 (74)</td>
<td>230/305 (75.4)</td>
</tr>
<tr>
<td>Deep location, no. (%)‡</td>
<td>182/535 (34)</td>
<td>132/413 (32)</td>
<td>103/302 (34.1)</td>
</tr>
<tr>
<td>Aneurysm, no. (%)</td>
<td>34/539 (6.3)</td>
<td>28/416 (6.7)</td>
<td>19/305 (6.2)</td>
</tr>
<tr>
<td>Deep venous drainage, no. (%)</td>
<td>345/539 (64)</td>
<td>256/416 (61.5)</td>
<td>192/305 (63)</td>
</tr>
<tr>
<td>SM grade, no. (%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>I</td>
<td>49/539 (9.1)</td>
<td>40/416 (9.6)</td>
<td>30/305 (9.8)</td>
</tr>
<tr>
<td>II</td>
<td>164/539 (30.4)</td>
<td>136/416 (32.7)</td>
<td>91/305 (29.8)</td>
</tr>
<tr>
<td>III</td>
<td>243/539 (45.1)</td>
<td>190/416 (45.7)</td>
<td>145/305 (47.5)</td>
</tr>
<tr>
<td>IV</td>
<td>72/539 (13.4)</td>
<td>45/416 (10.8)</td>
<td>34/305 (11.2)</td>
</tr>
<tr>
<td>V</td>
<td>11/539 (2)</td>
<td>5/416 (1.2)</td>
<td>5/305 (1.6)</td>
</tr>
<tr>
<td>VRAS, no. (%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0</td>
<td>10/539 (1.9)</td>
<td>8/416 (1.9)</td>
<td>5/305 (1.6)</td>
</tr>
<tr>
<td>1</td>
<td>75/539 (13.9)</td>
<td>63/416 (15.1)</td>
<td>37/305 (12.1)</td>
</tr>
<tr>
<td>2</td>
<td>183/539 (34)</td>
<td>145/416 (34.9)</td>
<td>115/305 (37.7)</td>
</tr>
<tr>
<td>3</td>
<td>157/539 (29.1)</td>
<td>115/416 (27.6)</td>
<td>81/305 (26.6)</td>
</tr>
<tr>
<td>4</td>
<td>114/539 (21.2)</td>
<td>85/416 (20.4)</td>
<td>67/305 (22)</td>
</tr>
<tr>
<td>RBAS: mean/median (SD)</td>
<td>1.0/0.8 (1.0)</td>
<td>0.9/0.8 (0.9)</td>
<td>0.9/0.8 (0.7)</td>
</tr>
<tr>
<td>Follow-up: mean/median (SD, IQR), mos</td>
<td>85.8/68.5 (66.6, 30.3–127.1)</td>
<td>76.9/52.2 (65.7, 26.4–108.8)</td>
<td>75.8/51.3 (65.2, 25.1–110.4)</td>
</tr>
</tbody>
</table>

* Initial SRS parameters.
† Sensorimotor, language, and visual cortex; hypothalamus and thalamus; internal capsule; brainstem; cerebellar peduncles; and deep cerebellar nuclei.
‡ Thalamus, basal ganglia, and brainstem.

RBAS = modified radiosurgery-based AVM score; VRAS = Virginia Radiosurgery AVM Scale; — = not applicable.
Discussion

In this multicenter study, we provided estimates of the long-term outcomes and risks of SRS for AVMs in the pediatric population. With a mean follow-up exceeding 7 years in a large cohort of pediatric AVM patients, favorable outcome was achieved in 57% of the overall population, which included those with previously treated AVMs and those who underwent repeat SRS. The higher rate of favorable outcome in the two subgroup analyses

<table>
<thead>
<tr>
<th>Outcome</th>
<th>Overall Cohort (n = 539)</th>
<th>Single-Session SRS (n = 416)</th>
<th>Single-Session SRS as Only Treatment (n = 305)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Favorable outcome</td>
<td>307/539 (57)</td>
<td>261/416 (62.7)</td>
<td>202/305 (66.2)</td>
</tr>
<tr>
<td>AVM obliteration</td>
<td>346/539 (64.3)</td>
<td>285/415 (68.7)</td>
<td>219/305 (71.8)</td>
</tr>
<tr>
<td>Post-SRS hemorrhage</td>
<td>45/539 (8.4)</td>
<td>21/416 (5.1)</td>
<td>14/305 (4.6)</td>
</tr>
<tr>
<td>Radiological RIC</td>
<td>202/526 (38.4)</td>
<td>148/406 (36.5)</td>
<td>120/297 (40.4)</td>
</tr>
<tr>
<td>Symptomatic RIC</td>
<td>55/536 (10.3)</td>
<td>35/413 (8.5)</td>
<td>22/303 (7.3)</td>
</tr>
<tr>
<td>Permanently symptomatic RIC</td>
<td>33/536 (6.2)</td>
<td>22/413 (5.3)</td>
<td>14/303 (4.6)</td>
</tr>
<tr>
<td>Delayed cyst</td>
<td>11/529 (2.1)</td>
<td>5/408 (1.2)</td>
<td>4/301 (1.3)</td>
</tr>
<tr>
<td>Symptomatic</td>
<td>3/522 (0.6)</td>
<td>0/403 (0)</td>
<td>0/297 (0)</td>
</tr>
<tr>
<td>Required intervention</td>
<td>2/522 (0.4)</td>
<td>0/403 (0)</td>
<td>0/297 (0)</td>
</tr>
<tr>
<td>Tumor</td>
<td>2/529 (0.4)</td>
<td>1/408 (0.3)</td>
<td>0/301 (0)</td>
</tr>
</tbody>
</table>

Values are presented as the number (%) of patients.
embolization has been shown to be a negative prognostic factor for post-SRS AVM obliteration, and repeat SRS may yield worse outcomes than initial SRS.\textsuperscript{10,21}

Due to the risk of hemorrhage and its associated morbidity and mortality, complete nidal obliteration remains the primary goal of any AVM treatment. SRS is an effective treatment for pediatric AVMs, especially for those not amenable to surgery, with reported obliteration rates ranging from 60\% to 80\% at 4–5 years after SRS.\textsuperscript{9,11,13,14,17,23,25,21}

In the current study comprising 539 pediatric AVM patients, obliteration was achieved in 64\% after a mean follow-up of 86 months. To avoid upward bias of incidence estimates, as seen when using the Kaplan-Meier survival function, cumulative incidence functions adjusted for the competing risk of death were used in the estimations of cumulative obliteration, post-SRS hemorrhage, and rates of adverse radiation effects in the current study.\textsuperscript{2} As such, the cumulative obliteration rates of the overall cohort were 64\%, 77\%, and 88\% over 5, 10, and 15 years, respectively.

Despite the long-term efficacy of SRS for AVMs, obliteration occurs in a delayed fashion, and patients remain at risk for AVM hemorrhage during the latency period between SRS and complete nidal occlusion. There-

\begin{table}[h]
\centering
\begin{tabular}{|l|c|}
\hline
Outcome & SM Grade I & II AVMs (n = 213) \\
\hline
Favorable outcome & 136/213 (63.9) \\
AVM obliteration & 148/212 (69.8) \\
Post-SRS hemorrhage & 11/213 (5.2) \\
Radiological RICs & 70/209 (33.5) \\
Symptomatic RICs & 15/212 (7.1) \\
Permanently symptomatic RICs & 10/212 (4.7) \\
Delayed cyst & 3/211 (1.4) \\
Symptomatic & 1/210 (0.5) \\
Required intervention & 1/210 (0.5) \\
Tumor & 1/211 (0.5) \\
\hline
\end{tabular}
\caption{Subgroup analysis of SM grade I and II AVMs}
\end{table}

\begin{figure}[h]
\centering
\includegraphics[width=\textwidth]{figure2}
\caption{Cumulative incidence functions and associated 95\% CIs for AVM obliteration (A), post-SRS hemorrhage (B), cyst formation (C), and tumor formation (D) after SRS for pediatric AVMs in the single-session SRS subgroup. Dashed vertical blue, purple, and yellow reference lines denote 5-, 10-, and 15-year time points after SRS. Figure is available in color online only.}
\end{figure}
fore, as a safety assessment, post-SRS hemorrhage rates are often compared to the natural history of untreated AVMs. Post-SRS hemorrhage occurred in 8.4% of patients in the current study, resulting in an incidence of 10.7 hemorrhages per 1000 patient-years (annual post-SRS hemorrhage rate of 1.1%). After adjustment for the competing risk of death, the cumulative incidence of post-SRS hemorrhage was 4.9%, 9.7%, and 14.5% over 5, 10, and 15 years, respectively. Obliteration after SRS is often regarded as a definitive cure. However, AVM recurrence after an apparently curative intervention has been reported, and this phenomenon is more frequently observed in pediatric patients. We observed 6 cases of postobliteration hemorrhage (1.7%) at a median interval of 3.5 years after obliteration. Although these hemorrhages could be attributed to recurrent AVMs or angiographically occult micronidi, they could not be confirmed based on the available data.

RICs are the most frequently observed adverse radiation effect after SRS for AVMs. In a systematic review of 51 studies comprising 6779 AVMs treated with any SRS approach (i.e., single session, staged, or repeat), Ilyas et al. reported radiological, symptomatic, and permanently symptomatic RIC rates of 35.5%, 9.2%, and 3.8%, respectfully. In the present study, RICs were radiologically evident in 38.4% of the overall cohort, including symptomatic and permanently symptomatic RICs in 10.3% and 6.2%, respectively. Although some overlap exists between patients in the systematic review and the current study, pediatric AVM patients appear to be slightly more susceptible to permanent RICs compared to pooled data from the literature.

Due to the relative rarity of post-SRS cysts in AVM patients and the prolonged follow-up necessary for their detection, estimating the incidence of delayed cyst formation has been challenging. The small sample sizes of individual studies and case series dedicated to cyst formation have also hampered an accurate estimation of their cumulative incidence. In a systematic review of 22 studies comprising 2619 patients, Ilyas et al. reported an overall cyst formation rate of 3%, with a mean latency period of 6.5 years after any SRS approach. Among the cysts identified in the review, 32.8% were symptomatic and 32.8% required surgical intervention. In the current study, cyst formation was observed in 2.1% of the cases, and of these post-SRS cysts, 27.3% were symptomatic and 18.2% required intervention. The incidence of cyst formation was 4.4 cysts per...
The risk of delayed tumor development after SRS is even more challenging to assess, and the extended interval between SRS and the development of secondary neoplasms may preclude an accurate estimation of risk. However, this risk may be of greater importance in children than in adults, given their relatively greater number of years at risk following SRS. In a previous study from the University of Virginia comprising 1309 AVM patients (pediatric and adult) treated with SRS, Starke et al. reported 3 cases of radiation-related neoplasms, including 2 meningiomas and 1 high-grade glioma, with cumulative incidences of 0%, 0.3%, and 2.6% at 3, 10, and 15 years, respectively. In a recent multicenter study assessing the risk of SRS-associated intracranial malignancy, the investigators observed no secondary intracranial malignancies among 1089 AVM patients (pediatric and adult) after a median follow-up of 8.1 years. Although there were no secondary intracranial malignancies in the current study, we found 2 cases (0.4%) of SRS-induced meningioma that were previously reported based on neuroimaging characteristics and behavior. Although no secondary intracranial malignancies were detected in the current study, SRS-associated malignant brain tumors have been reported in the literature. Since this risk appears to be higher than that found in the general population, longitudinal surveillance after SRS remains important.

It is important to note the limitations of this retrospective study. The results are dependent on the accuracy and reliability of data from each participating center and, therefore, may be subject to reporting bias. Due to the nature of each contributing institution as a tertiary referral center for AVM SRS, detailed follow-up data, such as functional, seizure, and educational outcomes, could not be provided for every patient. Our database did not allow differentiation between delayed strokes and RICs. Therefore, we concede that a minority of patients with symptomatic post-SRS complications could have suffered from delayed infarcts rather than RICs. Additionally, the effects of post-SRS hemorrhage on neurological or functional outcomes were not captured. Despite the large sample size and long follow-up duration of the current study, our analyses may still be insufficient for the detection of rare and very delayed SRS-associated complications, such as cyst and tumor formation. Due to the low incidences of cyst and tumor formation, we were unable to identify their respective risk factors. Furthermore, AVM recurrence after angiographically confirmed obliteration, which has been reported predominantly in pediatric patients, was not documented in this study. AVM treatments subsequent to post-SRS hemorrhage were not recorded.

Differences in outcomes and complications between the overall cohort and subgroup analyses may reflect selection biases and differences in baseline characteristics, and therefore, they should not be interpreted as an effect of a particular treatment approach. No direct comparisons against the natural history of pediatric AVMs could be made, as control (untreated) cohort data were not available. Furthermore, it is important to note that SRS is often reserved for AVMs with high surgical risks (i.e., SM grade III–V AVMs) or for patients who refuse craniotomy (i.e., SM grade I and II AVMs). However, this study was also not designed to compare the outcomes of SRS to those of resection for pediatric AVMs. Treatment algorithms for pediatric AVMs are subject to considerable variability, as they are biased by the expertise, experience, and preferences of the participating institutions and responsible physicians. The findings of the current study were limited to the pediatric population, and as such, they should not be generalized to the adult population. Since SM grade II and III AVMs comprised the majority of the study cohort, our results may not be generalizable to pediatric patients with high-grade (i.e., SM grade VI and V) AVMs. The majority of patients were treated at one of the 3 major SRS centers participating in the IRRF, and thus, the reported outcomes may not be generalizable to less experienced centers or to centers employing different techniques.

Conclusions

Complete obliteration can be expected in 60%–80% of pediatric AVMs treated with SRS over 5 years of follow-up. The annual post-SRS hemorrhage risk for pediatric AVMs is approximately 1%, which compares favorably with the natural history. Although nearly 40% of SRS-treated pediatric AVM patients will develop neuroimaging evidence of RICs, less than one-third of these cases have neurological manifestations. The cumulative rates of cyst and benign tumor formation were estimated to be 7% and 3% over 15 years, respectively. Although SRS-related malignancies were not detected in the pediatric AVM population, longitudinal surveillance in these patients remains prudent.

References


Disclosures
Dr. Grills reports less than 5% stock ownership in Greater Michigan Gamma Knife, where she also serves on the executive board of directors. Dr. Lunsford reports stock ownership in Elekta AB; he is a consultant for Insightec and DSMB. Dr. Kondziolka reports funding from Brainlab for research support in brain tumor imaging (not related to this study).

Author Contributions
Conception and design: Sheehan, Chen. Acquisition of data: Lee, Kano, Kearns, Tseng, Atik, Joshi, Huang, Mathieu, Iorio-Morin, Quinn, Siddiqui, Marvin, Feliciano, Faramand. Analysis and interpretation of data: Sheehan, Chen, Ding. Drafting the article: Chen, Ding. Critically revising the article: all authors. Reviewed, submitted version of manuscript: all authors. Statistical analysis: Chen. Administrative/technical/material support: Sheehan. Study supervision: Sheehan.

Supplemental Information
Previous Presentations
The contents of this study were orally presented at the 67th Annual Meeting of the Congress of Neurological Surgeons, October 19–23, 2019, San Francisco, California.

Correspondence
Jason P. Sheehan: University of Virginia Health System, Charlottesville, VA. jsheehan@virginia.edu.